BioDerm, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BioDerm, Inc. - overview
Established
1991
Location
Largo, FL, US
Primary Industry
Medical Devices & Equipment
About
BioDerm, Inc. is a US-based company specializing in innovative medical solutions for infection prevention and wound care, dedicated to improving patient health outcomes. BioDerm, Inc. , founded in 1991 and headquartered in Largo, US, focuses on developing medical products for wound care.
The company has undergone strategic pivots to enhance its portfolio and is recognized for its advanced solutions in infection management. It has secured investment from Mountaingate Capital in January 2021, supporting its growth initiatives. The company does not operate as a subsidiary of a larger firm and has not reported any recent mergers or acquisitions. BioDerm, Inc.
offers a range of specialized products aimed at infection prevention and wound care. Their key offerings include the Silverlon® antimicrobial wound dressings, designed with silver plated nylon technology for effective infection control, and the Men’s Liberty™ external urinary collection device for managing urinary incontinence. Additionally, the company provides antimicrobial cleansers and irrigation solutions, primarily targeting healthcare institutions like hospitals and clinics across the United States. BioDerm, Inc.
generates revenue through direct sales of its specialized wound care products to healthcare facilities, operating primarily on a B2B basis. Their flagship products, such as Silverlon® and Men’s Liberty™, are distributed through established channels, ensuring accessibility to healthcare providers and patients across the US. Pricing is structured according to contractual agreements with healthcare institutions, reflecting the clinical value of their offerings in improving patient care. BioDerm, Inc.
plans to leverage recent funding from Mountaingate Capital and Abacus Finance to enhance its product lineup and expand its market reach. The company is focusing on developing additional infection prevention solutions, with the goal of launching new products by the end of 2023. Furthermore, BioDerm, Inc. aims to enter new healthcare markets within North America by 2024, positioning itself to address growing needs in wound care and infection management.
Current Investors
Abacus Finance, Mountaingate Capital
Primary Industry
Medical Devices & Equipment
Sub Industries
Medical Supplies
Website
www.bioderminc.com
Verticals
Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
BioDerm, Inc. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Add-on | Completed | Argentum Medical, LLC | - | ||||||||
| Add-on, Trade Sale | Completed | Argentum Medical, LLC | - | ||||||||
| Growth | Completed | BioDerm, Inc. | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.